PD-Loma: a Cancer Entity with a Shared Sensitivity to the PD-1/PD-L1 Pathway Blockade

Overview

Journal Br J Cancer

Specialty Oncology

Date 2018 Nov 11

PMID 30413824

Citations 60

Authors

Laure Hirsch

Laurence Zitvogel

Alexander Eggermont

Aurelien Marabelle

Affiliations

Soon will be listed here.

Abstract

Clinical trials have now identified over 30 cancer histotypes with sensitivity to anti-PD-(L)1 therapies. It is the first time in oncology that a class of drugs has demonstrated such a wide spectrum of activity in monotherapy. This subgroup of cancers ('PD-Lomas') is driving the clinical research strategies for the next generation of combination immunotherapy.

Citing Articles

Enabling immune checkpoint blockade efficacy in T-lymphopenia by restoring CD8 T cell dynamics with IL-7 cytokine therapy.

Kang Y, Choi D, Moon D, Lee K, Oh Y, Yang J Front Immunol. 2025; 15:1477171.

PMID: 39763661 PMC: 11701376. DOI: 10.3389/fimmu.2024.1477171.

Targeting RGMb interactions: Discovery and preclinical characterization of potent anti-RGMb antibodies blocking multiple ligand bindings.

Meira M, Frey A, Chekkat N, Rybczynska M, Sellam Z, Park J MAbs. 2024; 16(1):2432403.

PMID: 39588913 PMC: 11601088. DOI: 10.1080/19420862.2024.2432403.

Enhancing Tumor Immunity with IL-12 and PD-1 Blockade: A Strategy for Inducing Robust Central Memory T Cell Responses in Resistant Cancer Model.

Chen F, Wu K, Lin S, Cui J, Chen X, Zeng Z Antibodies (Basel). 2024; 13(4).

PMID: 39584994 PMC: 11586976. DOI: 10.3390/antib13040094.

Tertiary lymphoid structure-related score as a predictor for survival prognosis and immunotherapy response in head and neck squamous cell carcinoma.

Wu F, Cao H, Ren S, Wu J, Liu X, Li Q Front Immunol. 2024; 15:1483497.

PMID: 39493749 PMC: 11527632. DOI: 10.3389/fimmu.2024.1483497.

Relapsing polychondritis: clinical updates and new differential diagnoses.

Mertz P, Costedoat-Chalumeau N, Ferrada M, Moulis G, Mekinian A, Grayson P Nat Rev Rheumatol. 2024; 20(6):347-360.

PMID: 38698240 DOI: 10.1038/s41584-024-01113-9.

References

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

Younes A, Santoro A, Shipp M, Zinzani P, Timmerman J, Ansell S . Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016; 17(9):1283-94. PMC: 5541855. DOI: 10.1016/S1470-2045(16)30167-X. View

Le D, Uram J, Wang H, Bartlett B, Kemberling H, Eyring A . PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015; 372(26):2509-20. PMC: 4481136. DOI: 10.1056/NEJMoa1500596. View

Robert C, Long G, Brady B, Dutriaux C, Maio M, Mortier L . Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2014; 372(4):320-30. DOI: 10.1056/NEJMoa1412082. View

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. View

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J . Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2016; 389(10066):255-265. PMC: 6886121. DOI: 10.1016/S0140-6736(16)32517-X. View

Motzer R, Tannir N, Mcdermott D, Frontera O, Melichar B, Choueiri T . Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018; 378(14):1277-1290. PMC: 5972549. DOI: 10.1056/NEJMoa1712126. View

Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N . Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. PMC: 5705936. DOI: 10.1056/NEJMoa1507643. View

Chen R, Zinzani P, Fanale M, Armand P, Johnson N, Brice P . Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. J Clin Oncol. 2017; 35(19):2125-2132. PMC: 5791843. DOI: 10.1200/JCO.2016.72.1316. View

10.

Ribas A, Hamid O, Daud A, Hodi F, Wolchok J, Kefford R . Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA. 2016; 315(15):1600-9. DOI: 10.1001/jama.2016.4059. View

11.

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J, Cowey C, Lao C . Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015; 373(1):23-34. PMC: 5698905. DOI: 10.1056/NEJMoa1504030. View

12.

Routy B, Le Chatelier E, Derosa L, Duong C, Alou M, Daillere R . Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2017; 359(6371):91-97. DOI: 10.1126/science.aan3706. View

13.

Migden M, Rischin D, Schmults C, Guminski A, Hauschild A, Lewis K . PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018; 379(4):341-351. DOI: 10.1056/NEJMoa1805131. View

14.

Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T . Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. J Clin Oncol. 2015; 33(34):4015-22. DOI: 10.1200/JCO.2015.62.3397. View

15.

Seiwert T, Burtness B, Mehra R, Weiss J, Berger R, Eder J . Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016; 17(7):956-965. DOI: 10.1016/S1470-2045(16)30066-3. View

16.

Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz L, Mandrekar S . iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017; 18(3):e143-e152. PMC: 5648544. DOI: 10.1016/S1470-2045(17)30074-8. View